TITLE

Observatory. Cancer

PUB. DATE
September 2012
SOURCE
MLO: Medical Laboratory Observer;Sep2012, Vol. 44 Issue 9, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports a study which discovered a key factor, a type of normal, noncancerous cell, the fibroblast, sustains DNA damage that drives the production of a broad spectrum of growth factors that stimulate cancer growth.
ACCESSION #
79793000

 

Related Articles

  • Predicting Sensitivity of Non—Small-Cell Lung Cancer to Gefitinib: Is There a Role for P-Akt? Pao, William; Miller, Vincent A.; Venkatraman, Ennapadam; Kris, Mark G. // JNCI: Journal of the National Cancer Institute;8/4/2004, Vol. 96 Issue 15, p1117 

    Explores the role of phosphatidylinositol 3-kinase/Akt in predicting sensitivity of non-small-cell lung cancer (NSCLC) to gefitinib. Inhibition of epidermal growth factor receptor (EGFR) by gefitinib; Association of mutations in the tyrosine kinase domain of EGFR with gefitinib sensitivity in...

  • VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. Currier, Mark A; Eshun, Francis K; Sholl, Allyson; Chernoguz, Artur; Crawford, Kelly; Divanovic, Senad; Boon, Louis; Goins, William F; Frischer, Jason S; Collins, Margaret H; Leddon, Jennifer L; Baird, William H; Haseley, Amy; Streby, Keri A; Wang, Pin-Yi; Hendrickson, Brett W; Brekken, Rolf A; Kaur, Balveen; Hildeman, David; Cripe, Timothy P // Molecular Therapy;May2013, Vol. 21 Issue 5, p1014 

    Understanding the host response to oncolytic viruses is important to maximize their antitumor efficacy. Despite robust cytotoxicity and high virus production of an oncolytic herpes simplex virus (oHSV) in cultured human sarcoma cells, intratumoral (ITu) virus injection resulted in only mild...

  • Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance. Gonzalez de Castro, D; Clarke, P A; Al-Lazikani, B; Workman, P // Clinical Pharmacology & Therapeutics;Mar2013, Vol. 93 Issue 3, p252 

    The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for...

  • The cancer-associated fibroblasts and drug resistance. LI, X.-Y.; HU, S.-Q.; XIAO, L. // European Review for Medical & Pharmacological Sciences;2015, Vol. 19 Issue 11, p2112 

    The present treatment of solid tumors is plagued by drug resistance. Despite continued development of meticulously designed therapeutic scheme, cancer cells remain poorly being completely eliminated. Because therapeutic resistance is a problem with the drug used in cancer therapy, most of the...

  • Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Oei, Arlene L.; Vriend, Lianne E. M.; Crezee, Johannes; Franken, Nicolaas A. P.; Krawczyk, Przemek M. // Radiation Oncology;Aug2015, Vol. 10 Issue 1, p1 

    The currently available arsenal of anticancer modalities includes many DNA damaging agents that can kill malignant cells. However, efficient DNA repair mechanisms protect both healthy and cancer cells against the effects of treatment and contribute to the development of drug resistance....

  • Recent Approaches to Improve the Antitumor Efficacy of Temozolomide. Tentori, Lucio; Graziani, Grazia // Current Medicinal Chemistry;Jan2009, Vol. 16 Issue 3, p245 

    Temozolomide (TMZ) is an oral anticancer agent approved for the treatment of newly diagnosed glioblastoma in combination with radiotherapy. Moreover, TMZ has shown comparable efficacy with respect to dacarbazine, the reference drug for metastatic melanoma. Due to its favorable toxicity and...

  • DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets. Kasap, Corynn; Elemento, Olivier; Kapoor, Tarun M // Nature Chemical Biology;Aug2014, Vol. 10 Issue 8, p626 

    To identify physiological targets of drugs and bioactive small molecules, we developed an approach, named DrugTargetSeqR, which combines high-throughput sequencing, computational mutation discovery and clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-based genome editing....

  • Saccharomyces cerevisiae as a model system to study the response to anticancer agents. Matuo, Renata; Sousa, Fabrício; Soares, Daniele; Bonatto, Diego; Saffi, Jenifer; Escargueil, Alexandre; Larsen, Annette; Henriques, João // Cancer Chemotherapy & Pharmacology;Oct2012, Vol. 70 Issue 4, p491 

    The development of new strategies for cancer therapeutics is indispensable for the improvement of standard protocols and the creation of other possibilities in cancer treatment. Yeast models have been employed to study numerous molecular aspects directly related to cancer development, as well as...

  • Isoliquiritigen Enhances the Antitumour Activity and Decreases the Genotoxic Effect of Cyclophosphamide. Hong Zhao; Xuan Yuan; Defang Li; Hongmei Chen; Jiangtao Jiang; Zhiping Wang; Xiling Sun; Qiusheng Zheng // Molecules;Aug2013, Vol. 18 Issue 8, p8786 

    The aim of this study was to evaluate the antitumour activities and genotoxic effects of isoliquiritigenin (ISL) combined with cyclophosphamide (CP) in vitro and in vivo. U14 cells were treated with either of ISL (5-25 μg/mL) or CP (0.25-1.25 mg/mL) alone or with combination of ISL (5-25...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics